Literature DB >> 21347632

Retiform Sertoli-Leydig cell tumor of ovary in a 9-year-old girl: case report and review of the literature.

Weizhen Lou1, Dongyan Cao, Jiaxin Yang, Lina Guo, Keng Shen.   

Abstract

The management of the retiform variant of Sertoli-Leydig cell tumor remains a challenge for the gynecologist. Surgery is the preferred treatment, but it is still inconclusive whether complete staging or postoperative adjuvant therapy is necessary. A 9-year-old girl was admitted with a well-circumscribed, solid cystic mass in the lower abdomen, of size corresponding to a 20-week gravid uterus, without any androgenic manifestations. Per-operatively, the mass arose from left ovary, which had a smooth outer surface with intact capsule. A cut section was almost multiloculated with cysts ranging from 0.5 to 2.5 cm in diameter and filled with thin yellow or brown serous fluid. Left salpingo-oophorectomy, bilateral lymph node dissection, infracolic omentectomy and appendectomy were performed. The pathological diagnosis was retiform pattern of intermediate to poorly differentiated Sertoli-Leydig cell tumor. The clinical stage was IA. The patient was followed up 3-monthly, and was disease-free at 18-month follow-up after the initial treatment. After review of the literature, we conclude that the retiform variant is a special subtype of Sertoli-Leydig cell tumors. Because of their young age, the uncertain malignant potential and rare bilaterality, patients should be treated conservatively whenever possible. There is at present no good evidence that postoperative adjuvant therapy is effective in preventing recurrence.

Entities:  

Mesh:

Year:  2011        PMID: 21347632     DOI: 10.1007/s10147-011-0186-6

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  13 in total

1.  Surgical resection alone is effective treatment for ovarian immature teratoma in children and adolescents: a report of the pediatric oncology group and the children's cancer group.

Authors:  B Cushing; R Giller; A Ablin; L Cohen; J Cullen; E Hawkins; S A Heifetz; M Krailo; S J Lauer; N Marina; P V Rao; F Rescorla; C D Vinocur; R M Weetman; R P Castleberry
Journal:  Am J Obstet Gynecol       Date:  1999-08       Impact factor: 8.661

2.  Calretinin, a more sensitive but less specific marker than alpha-inhibin for ovarian sex cord-stromal neoplasms: an immunohistochemical study of 215 cases.

Authors:  Saeid Movahedi-Lankarani; Robert J Kurman
Journal:  Am J Surg Pathol       Date:  2002-11       Impact factor: 6.394

3.  Sertoli-Leydig cell tumor.

Authors:  T Lantzsch; S Stoerer; K Lawrenz; J Buchmann; H G Strauss; H Koelbl
Journal:  Arch Gynecol Obstet       Date:  2001-01       Impact factor: 2.344

Review 4.  Value of inhibin staining in gynecological pathology.

Authors:  W G McCluggage
Journal:  Int J Gynecol Pathol       Date:  2001-01       Impact factor: 2.762

5.  Trisomy 8 as sole karyotypic aberration in an ovarian metastasizing Sertoli-Leydig cell tumor.

Authors:  E Manegold; L Tietze; K Günther; A Fleischer; B K Amo-Takyi; W Schröder; S Handt
Journal:  Hum Pathol       Date:  2001-05       Impact factor: 3.466

6.  Ovarian Sertoli-Leydig cell tumors with a retiform pattern: a problem in histopathologic diagnosis. A report of 25 cases.

Authors:  R H Young; R E Scully
Journal:  Am J Surg Pathol       Date:  1983-12       Impact factor: 6.394

Review 7.  Management of ovarian stromal cell tumors.

Authors:  Nicoletta Colombo; Gabriella Parma; Vanna Zanagnolo; Alessandra Insinga
Journal:  J Clin Oncol       Date:  2007-07-10       Impact factor: 44.544

8.  Treatment of poor-prognosis sex cord-stromal tumors of the ovary with the combination of bleomycin, etoposide, and cisplatin.

Authors:  D M Gershenson; M Morris; T W Burke; C Levenback; C M Matthews; J T Wharton
Journal:  Obstet Gynecol       Date:  1996-04       Impact factor: 7.661

9.  Sertoli-Leydig cell tumors: a clinicopathologic study of 34 cases.

Authors:  L M Roth; M C Anderson; A D Govan; F A Langley; N F Gowing; A S Woodcock
Journal:  Cancer       Date:  1981-07-01       Impact factor: 6.860

Review 10.  Ovarian Sertoli-Leydig cell tumors. A clinicopathological analysis of 207 cases.

Authors:  R H Young; R E Scully
Journal:  Am J Surg Pathol       Date:  1985-08       Impact factor: 6.394

View more
  2 in total

Review 1.  Sertoli - Leydig cell tumor with retiform areas and overgrowth of rhabdomyosarcomatous elements: case report and literature review.

Authors:  T Burnik Papler; S Frković Grazio; B Kobal
Journal:  J Ovarian Res       Date:  2016-07-30       Impact factor: 4.234

2.  Retiform Sertoli-Leydig Cell Tumor in a 38-Year-Old Woman: A Case Report, Retrospective Review, and Review of Current Literature.

Authors:  Laura C Nwogu; Josh A Showalter; Suvra Roy; Michael T Deavers; Bihong Zhao
Journal:  Case Rep Pathol       Date:  2017-02-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.